Stockscreener 앱 받기
7.05
1.67%
-0.12
시간 외 거래:
7.15
0.10
+1.42%
전일 마감가:
$7.17
열려 있는:
$7.25
하루 거래량:
1.14M
Relative Volume:
1.84
시가총액:
$193.12M
수익:
$675.00K
순이익/손실:
$-26.62M
주가수익비율:
-4.4896
EPS:
-1.5703
순현금흐름:
$-31.34M
1주 성능:
-8.32%
1개월 성능:
-14.65%
6개월 성능:
+29.36%
1년 성능:
+926.65%
1일 변동 폭
$6.96
$7.36
1주일 범위
$6.96
$8.055
52주 변동 폭
$0.601
$8.74
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
명칭
Unicycive Therapeutics Inc
전화
650-384-0642
주소
1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW
Compare UNCY vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
7.05 | 195.04M | 675.00K | -26.62M | -31.34M | -1.5703 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-21 | 개시 | Guggenheim | Buy |
| 2024-04-04 | 개시 | Piper Sandler | Overweight |
Unicycive Therapeutics Inc 주식(UNCY)의 최신 뉴스
[EFFECT] Unicycive Therapeutics, Inc. SEC Filing - Stock Titan
Unicycive (NASDAQ: UNCY) CEO receives 762,200 restricted stock units - Stock Titan
Unicycive Therapeutics (UNCY) director receives sizeable new RSU awards - Stock Titan
Director Laumas receives new RSU awards at Unicycive (NASDAQ: UNCY) - Stock Titan
Executive at Unicycive (UNCY) granted 169,500 restricted stock units - Stock Titan
Unicycive Therapeutics (UNCY) CFO awarded 169,500 RSUs as stock compensation - Stock Titan
Unicycive Therapeutics (UNCY) EVP receives 169,500 RSU equity award - Stock Titan
Number of shareholders of Unicycive Therapeutics, Inc. – NASDAQ:UNCY - TradingView
UNCY Q1 2026 Earnings: Wider-Than-Expected Loss Amid No Revenue, Shares SlipEarnings Acceleration Picks - newsline.com
Will Unicycive's OLC Clear The FDA Hurdle And Become An Attractive New Option For Hyperphosphatemia? - RTTNews
Hyperphosphatemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Ardelyx, Sanofi, Takeda Pharma, Unicycive Therapeutics, Taisho Pharma, Alebund Pharma - Barchart.com
Hyperphosphatemia Market Unlocking New Revenue Opportunities - openPR.com
Unicycive Expands At-The-Market Equity Offering Program - The Globe and Mail
Unicycive Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Unicycive Therapeutics Raises ATM Offering of Shares - Moomoo
Unicycive (NASDAQ: UNCY) boosts ATM capacity, files $50M S-3 shelf - Stock Titan
Unicycive Therapeutics (UNCY) registers $150M shelf; $50M ATM with Guggenheim - Stock Titan
Unicycive Therapeutics director Gaurav Aggarwal resigns from board By Investing.com - Investing.com Australia
Unicycive shares edge up as biotech looks to June FDA meeting and analyst lifts target - Bez Kabli
Unicycive Therapeutics director Gaurav Aggarwal resigns from board - Investing.com
UNCY Q1 2026 Earnings: Pre‑Revenue Biotech Reports Wider‑Than‑Expected Loss, Stock Edges Higher - newsline.com
UNCY Maintained by Benchmark -- Price Target Raised to $18.00 - GuruFocus
Benchmark raises Unicycive Therapeutics price target on FDA review By Investing.com - Investing.com Canada
Interview: Unicycive’s CEO on Biotech Innovation vs. Payer Reality - NAVLIN DAILY
UNCY: Upcoming Virtual Meeting Announced for May 29 - GuruFocus
H.C. Wainwright reiterates Unicycive stock rating on manufacturing progress By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Unicycive stock rating on manufacturing progress - Investing.com
Unicycive Therapeutics (UNCY) Edges Higher as Stock Tests Key Resistance Near $7.46Wide Range Bar - newsline.com
Unicycive Therapeutics Inc. (UNCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Unicycive Therapeutics (UNCY) Surges 5.9% as Shares Test Key ResistancePairs Trade - Newser
Unicycive Therapeutics (UNCY) CEO receives 762,200 restricted stock units award - Stock Titan
Unicycive Therapeutics (UNCY) director granted 126,300 RSUs as equity pay - Stock Titan
Unicycive CEO left clinical medicine to develop kidney disease therapies - The Business Journals
Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside - Seeking Alpha
Unicycive (NASDAQ: UNCY) EVP receives 169,500 RSUs as stock award - Stock Titan
Unicycive (UNCY) EVP receives 169,500 RSUs vesting over 3 years - Stock Titan
Unicycive (UNCY) CFO receives 169,500 restricted stock units as equity pay - Stock Titan
Unicycive Therapeutics (UNCY) Drops -4.29% — Key Support at $7.41 2026-05-19Risk Analysis - Newser
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Unicycive Therapeutics (UNCY) price target decreased by 23.53% to 32.20 - MSN
Unicycive (UNCY) director Sandeep Laumas granted two new RSU awards - Stock Titan
RA Capital affiliates hold 2.80M shares in Unicycive (UNCY) under 9.99% blocker - Stock Titan
TradingKey - TradingKey
Unicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing? - Yahoo Finance
Unicycive Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Noble Financial Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Guggenheim lowers Unicycive stock price target on higher costs By Investing.com - Investing.com Canada
Guggenheim Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
Unicycive Therapeutics stock (US90467V1098): Q1 2026 results and PDUFA update - AD HOC NEWS
Unicycive Therapeutics Reports Q1 2026 Financial Results, FDA Review Progress for Oxylanthanum Carbonate NDA, and Commercial Launch Preparations - Minichart
Unicycive Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Unicycive Therapeutics Inc (UNCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):